SK7012003A3 - Fibroblast growth factors - Google Patents

Fibroblast growth factors Download PDF

Info

Publication number
SK7012003A3
SK7012003A3 SK701-2003A SK7012003A SK7012003A3 SK 7012003 A3 SK7012003 A3 SK 7012003A3 SK 7012003 A SK7012003 A SK 7012003A SK 7012003 A3 SK7012003 A3 SK 7012003A3
Authority
SK
Slovakia
Prior art keywords
fgf
polypeptide
composition
amino acid
leu
Prior art date
Application number
SK701-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Peter W Bringmann
Daryl Faulds
Branislava Mitrovic
Subha Srinivasan
James Onuffer
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of SK7012003A3 publication Critical patent/SK7012003A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK701-2003A 2000-12-08 2001-12-10 Fibroblast growth factors SK7012003A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25183700P 2000-12-08 2000-12-08
US10/005,646 US20020151496A1 (en) 2000-12-08 2001-12-07 Novel fibroblast growth factors
PCT/US2001/047350 WO2002046424A2 (en) 2000-12-08 2001-12-10 Fibroblast growth factors

Publications (1)

Publication Number Publication Date
SK7012003A3 true SK7012003A3 (en) 2004-04-06

Family

ID=26674594

Family Applications (1)

Application Number Title Priority Date Filing Date
SK701-2003A SK7012003A3 (en) 2000-12-08 2001-12-10 Fibroblast growth factors

Country Status (21)

Country Link
US (2) US20020151496A1 (es)
EP (1) EP1389237A2 (es)
JP (1) JP2005506275A (es)
KR (1) KR20040052442A (es)
CN (1) CN1518597A (es)
AU (1) AU2603402A (es)
BG (1) BG107888A (es)
BR (1) BR0116507A (es)
CA (1) CA2431374A1 (es)
CZ (1) CZ20031570A3 (es)
EE (1) EE200300269A (es)
HU (1) HUP0400657A1 (es)
IL (1) IL156259A0 (es)
MX (1) MXPA03005142A (es)
NO (1) NO20032573L (es)
PL (1) PL366158A1 (es)
RU (1) RU2329058C2 (es)
SI (1) SI21372A (es)
SK (1) SK7012003A3 (es)
WO (1) WO2002046424A2 (es)
ZA (1) ZA200305236B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
US20050176631A1 (en) * 2002-01-15 2005-08-11 Heuer Josef G. Method for reducing morbidity and mortality in critically ill patients
WO2004090112A2 (en) 2003-04-01 2004-10-21 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
WO2004105787A1 (en) * 2003-05-28 2004-12-09 The University Of Kyoto Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders
CN105601748B (zh) 2011-07-01 2021-08-27 恩格姆生物制药公司 用于代谢病症和疾病治疗的组合物、应用和方法
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
CN105008548B (zh) 2012-12-27 2020-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态以及治疗胆汁酸紊乱和疾病的方法
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
ES2808340T3 (es) 2014-01-24 2021-02-26 Ngm Biopharmaceuticals Inc Anticuerpos que se unen al dominio de beta klotho 2 y procedimientos de uso de los mismos
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL251834B2 (en) 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc Pharmaceutical compositions containing peptide variants and methods of using them
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
CA3082794A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals Inc. Methods for treatment of bile acid-related disorders
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000060085A1 (en) * 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
EP1224283A2 (en) * 1999-10-22 2002-07-24 Chiron Corporation Human and rat fgf-20 genes and gene expression products
CA2392103A1 (en) * 1999-11-18 2001-05-25 Chiron Corporation Human fgf-21 gene and gene expression products
WO2001092522A2 (en) * 2000-06-01 2001-12-06 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
AU7181101A (en) * 2000-07-03 2002-01-14 Curagen Corp Novel fibroblast growth factors and nucleic acids encoding same

Also Published As

Publication number Publication date
EE200300269A (et) 2003-10-15
BG107888A (bg) 2004-08-31
RU2003119657A (ru) 2005-02-27
IL156259A0 (en) 2004-01-04
US20080057076A1 (en) 2008-03-06
MXPA03005142A (es) 2004-10-15
WO2002046424A2 (en) 2002-06-13
WO2002046424A3 (en) 2003-11-27
NO20032573L (no) 2003-07-22
CN1518597A (zh) 2004-08-04
HUP0400657A1 (en) 2006-04-28
AU2002226034A2 (en) 2002-06-18
CA2431374A1 (en) 2002-06-13
ZA200305236B (en) 2005-06-29
PL366158A1 (en) 2005-01-24
CZ20031570A3 (cs) 2004-01-14
KR20040052442A (ko) 2004-06-23
US20020151496A1 (en) 2002-10-17
RU2329058C2 (ru) 2008-07-20
SI21372A (sl) 2004-06-30
NO20032573D0 (no) 2003-06-06
BR0116507A (pt) 2004-01-06
JP2005506275A (ja) 2005-03-03
AU2603402A (en) 2002-06-18
EP1389237A2 (en) 2004-02-18

Similar Documents

Publication Publication Date Title
US20080057076A1 (en) Novel fibroblast growth factors
KR100924183B1 (ko) 신규 섬유아세포 성장 인자 (fgf23) 및 그의 이용 방법
KR100728405B1 (ko) Nogo 유전자의 뉴클레오티드와 단백질 서열 및 이들에기초한 방법
AU769166B2 (en) Fizz proteins
JP2002513037A5 (es)
WO1998007736A9 (en) Don-1 gene and polypeptides and uses therefor
AU4154097A (en) Don-1 gene and polypeptides and uses therefor
AU2002226034B2 (en) Fibroblast growth factors
US5750365A (en) Isolated nucleic acid encoding a newt acidic fibroblast growth factor (AFGF)
KR20030074588A (ko) 글리코실화 vegf-b 및 가용성 vegf-b 의 양을증가시키는 방법
AU2002226034A1 (en) Fibroblast growth factors
AU2007203341A1 (en) Fibroblast growth factors
US6537554B1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
CA2335326A1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US20020127594A1 (en) Don-1 gene and polypeptides and uses therefor
US20030104573A1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure